Zonegran(zonisamide)
Zonegran, Zonisade (zonisamide) is a small molecule pharmaceutical. Zonisamide was first approved as Zonegran on 2000-03-27. It is used to treat epilepsy and partial epilepsies in the USA. It has been approved in Europe to treat epilepsy and partial epilepsies. It is known to target carbonic anhydrase 7, carbonic anhydrase 12, and carbonic anhydrase 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Zonegran, Zonisade (generic drugs available since 2005-12-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| partial epilepsies | EFO_0004263 | D004828 | — |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | 6 | 9 | 3 | 19 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 6 | 3 | 1 | 1 | 11 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 3 | 1 | 1 | 1 | 6 |
| Seizures | D012640 | G40.4 | — | — | 2 | 1 | 1 | 4 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | 1 | 1 | 3 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | 1 | 1 | 3 |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | — | 2 | — | 2 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | 1 | — | 2 |
| Parkinsonian disorders | D020734 | HP_0001300 | — | — | — | 1 | — | 1 | |
| Dyskinesias | D020820 | G24 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 1 | — | — | 2 |
| Psychotic disorders | D011618 | F20.81 | — | 1 | 1 | — | — | 2 | |
| Smoking cessation | D016540 | EFO_0004319 | — | — | 2 | — | — | 2 | |
| Weight gain | D015430 | HP_0004324 | — | — | 1 | — | — | 1 | |
| Complex partial epilepsy | D017029 | EFO_1000877 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Noise-induced hearing loss | D006317 | EFO_1001254 | 1 | 3 | — | — | — | 3 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | — | — | — | 2 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 1 | — | — | 1 | 2 |
| Tobacco use disorder | D014029 | F17 | 1 | 1 | — | — | — | 1 | |
| Cocaine-related disorders | D019970 | F14 | 1 | 1 | — | — | — | 1 | |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | — | — | 6 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ZONISAMIDE |
| INN | zonisamide |
| Description | Zonisamide is a 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position. It has a role as an anticonvulsant, an antioxidant, a central nervous system drug, a protective agent and a T-type calcium channel blocker. It is a member of 1,2-benzoxazoles and a sulfonamide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)Cc1noc2ccccc12 |
Identifiers
| PDB | — |
| CAS-ID | 68291-97-4 |
| RxCUI | 39998 |
| ChEMBL ID | CHEMBL750 |
| ChEBI ID | 10127 |
| PubChem CID | 5734 |
| DrugBank | DB00909 |
| UNII ID | 459384H98V (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,887 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
78,892 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more